|
Carcinoma breast stage IV
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our study has uncovered high FOXA1-induced enhancer reprogramming and HIF-2α-dependent transcriptional programs as vulnerable targets for treating endocrine-resistant and metastatic breast cancer.
|
31826955 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conclusions<i>:</i> These data outline either HIF-2α and NEDDylation as two novel putative therapeutic targets to interfere with the procarcinogenic role of SerpinB3 in the development of HCC.
|
31817100 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It would be fair to announce that combine targeting for both hypoxia inducible factor (HIF)-1α and HIF-2α may hold a therapeutic promise for high-stage tumors, but an ongoing research is required to direct this hypothesis toward certainty.
|
31816327 |
2020 |
|
Chronic Kidney Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
However, our studies have demonstrated that the promoter regions of the genes encoding EPO and HIF2α are highly methylated in MF-REP cells, and the expression of these genes is epigenetically silenced with CKD progression.
|
31798631 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF-2α knockdown (KD) in steatotic HCC ameliorated triglyceride accumulation and steatosis.
|
31796646 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated that HIF-2α was elevated in tissues from NAFLD-HCC patients and was associated with survival.
|
31796646 |
2019 |
|
Steatohepatitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
HIF-2α knockdown (KD) in steatotic HCC ameliorated triglyceride accumulation and steatosis.
|
31796646 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Myocyte-specific Hif2a or ErbB1 knockout mice were generated to observe the effect of Hif2a knockdown in regulating ERBB1 expression and to examine the role of ERBB1 during myocardial ischemia and reperfusion injury.
|
31794514 |
2020 |
|
Myocardial Ischemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Myocyte-specific Hif2a or ErbB1 knockout mice were generated to observe the effect of Hif2a knockdown in regulating ERBB1 expression and to examine the role of ERBB1 during myocardial ischemia and reperfusion injury.
|
31794514 |
2020 |
|
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our aim was to evaluate the LincR-Gng2-5' and LincR-Epas1-3'AS fold change in blood of MS patients versus healthy controls and correlate it with disease severity, assessed based on Expanded Disability Status Scale (EDSS).<b>Material and Methods:</b> Sixty MS patients 42 relapsing remitting (RR, RRMS), 18 Secondary progressive (SP, SPMS) and sixty controls (age-matched and sex-matched) were studied.
|
31790618 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study revealed that the cartilage protective effect of osthole in a MIA-induced osteoarthritis (OA) murine model can be explained by downregulation of COX-2 and RUNX2 by inhibition of NF-κB and HIF-2α up-regulated by OA induction, resulting in downregulation of MMP-13, Syndecan IV and ADAMTS-5.
|
31765607 |
2020 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our results indicate that increased expression of MTFR2 is associated with tumour progression in breast cancer cells through switching glucose metabolism from OXPHS to glycolysis in a HIF1α- and HIF2α-dependent manner.
|
31740625 |
2019 |
|
Adult Liver Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Administration of a HIF-2α antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressed liver cancer.
|
31735169 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Administration of a HIF-2α antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressed liver cancer.
|
31735169 |
2019 |
|
Malignant neoplasm of liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Administration of a HIF-2α antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressed liver cancer.
|
31735169 |
2019 |
|
Age related macular degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study provides the groundwork necessary to establish safety profiles for strategies aiming at antagonizing HIF1A and HIF2A function in cone photoreceptors for the treatment of retinal degenerative diseases that involve a hypoxic component such as AMD.
|
31695081 |
2019 |
|
Psoriasis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Therefore, PHD and HIF-2α could be a new strategy for treatment of atopic dermatitis and psoriasis.
|
31682627 |
2019 |
|
Dermatitis, Atopic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, PHD and HIF-2α could be a new strategy for treatment of atopic dermatitis and psoriasis.
|
31682627 |
2019 |
|
Eczema
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, PHD and HIF-2α could be a new strategy for treatment of atopic dermatitis and psoriasis.
|
31682627 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results reveal that high level of oestrogen can aggravate the degenerative changes of mandibular condylar cartilage, while lack of oestrogen can alleviate it via oestrogen-ERβ-HIF2α pathway during TMJ OA progression.
|
31678498 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
HIF-2α-dependent cell migration/invasion decreased in GSCs treated with ADA under hypoxia.
|
31671624 |
2019 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study highlights adipocyte HIF-2α as a putative drug target against atherosclerosis.
|
31668872 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study highlights adipocyte HIF-2α as a putative drug target against atherosclerosis.
|
31668872 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on these findings we propose that, as tumors evolve, the accumulation of SOD2<sup>K68Ac</sup> turns on a mitochondrial pathway to stemness that depends on HIF2α and may be relevant for the progression of breast cancer toward poor outcomes.
|
31591207 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on these findings we propose that, as tumors evolve, the accumulation of SOD2<sup>K68Ac</sup> turns on a mitochondrial pathway to stemness that depends on HIF2α and may be relevant for the progression of breast cancer toward poor outcomes.
|
31591207 |
2019 |